Research programme: microbial compounds - Biosortia Pharmaceuticals

Drug Profile

Research programme: microbial compounds - Biosortia Pharmaceuticals

Latest Information Update: 07 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Biosortia Pharmaceuticals
  • Developer Biosortia Pharmaceuticals; Nationwide Children's Hospital; The Ohio State University Comprehensive Cancer Center
  • Class Small molecules
  • Mechanism of Action Immunostimulants; Interleukin 17 modulators; PCSK9 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Arthritis; Cancer; Hypercholesterolaemia; Liver cancer; Neuroblastoma; Psoriasis; Seizures

Most Recent Events

  • 06 Jun 2016 Early research in Arthritis in USA (unspecified route) (Biosortia Pharmaceuticals pipeline, June 2016)
  • 06 Jun 2016 Early research in Hypercholesterolaemia in USA (unspecified route) (Biosortia Pharmaceuticals pipeline, June 2016)
  • 06 Jun 2016 Early research in Psoriasis in USA (unspecified route) (Biosortia Pharmaceuticals pipeline, June 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top